Vimarsana
Biggest News Aggregation in the World

Page 11 - Patrick Barth News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Patrick Barth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Patrick Barth Today - Breaking & Trending Today

F. Hoffmann-La Roche Ltd: Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine - Vimarsana News

F. Hoffmann-La Roche Ltd: Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine

FIREFISH Part 1 data show treatment with Evrysdi at 12 months helped 90% of these infants survive without permanent ventilation and 33% sit without support, a key motor milestone not normally seen in the

F. Hoffmann-La Roche Ltd: FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients - Vimarsana News

F. Hoffmann-La Roche Ltd: FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients

(2) FDA BDD acknowledges the importance of GDF-15 testing in identifying eligible cachexic patients with solid tumours to be treated with Pfizer's investigational drug PF-06946860 Unintentional weight loss (cachexia) is a highly prevalent complication of cancer, affecting more than half of all cancer patients worldwide, potentially leading to significant functional impairment and increased risk of death Successful cachexia treatment can potentially contribute to improved cancer treatment worldwide Basel, 8 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food a...

FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients - Vimarsana News

FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients

FDA BDD acknowledges the importance of GDF-15 testing in identifying eligible cachexic patients with solid tumours to be treated with Pfizer's...

F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020 - Vimarsana News

F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020

F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020 Group sales increase 1% 1 at constant exchange rates (CER); 5% decline in Swiss francs, as a result of continued appreciation of the Swiss franc against most currencies Pharmaceuticals Division sales decline 2%; continued strong sales growth of newly launched medicines (+32% 2, including Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla) largely offsets the impact of competition from biosimilars (CHF -5.1 billion at CER 3), but not the additional COVID-19-related impact from missed medical appointments Diagnostics Division sales gr...

F. Hoffmann-La Roche Ltd: Roche renews partnership with Sysmex to deliver haematology testing solutions - Vimarsana News

F. Hoffmann-La Roche Ltd: Roche renews partnership with Sysmex to deliver haematology testing solutions

F. Hoffmann-La Roche Ltd: Roche renews partnership with Sysmex to deliver haematology testing solutions This successful long-running partnership continues to evolve and bring haematology testing innovations to laboratories, globally The new agreement aims to utilise the IT systems to lead to improved clinical decision making and customer experience Blood disorders have a high impact, not only for patients but for society as a whole, accounting for a third of all central laboratory tests 1 Basel, 25 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that, on 14 December, 2020, i...